NeoPharm (NEOL) Reports a Q4 Loss, Sees Operations Funded Through 2009
More News related to NEOL
- NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
- NeoPharm Names Dr. Aquilur Rahman as President and CEO
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
More News related to Earnings
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Needham Lifts Price Target on Dyax (DYAX) to $8
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
NeoPharm, Inc. (NASDAQ: NEOL) reports a Q4 loss of $0.04 (ex-items), as compared to a net loss of $0.28 per share, for the same period last year.
While NeoPharm anticipates future cash consumption levels to be in-line with spending during the fourth quarter, obligations related to previous drug product candidates’ trials are likely to be paid in the coming quarters. Despite these anticipated disbursements, with $20.8 million in cash and other investments at the end of the fourth quarter, the Company reaffirmed its estimate that it has adequate resources to fund its operations through most of 2009.
NeoPharm, Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of cancer. [SM]
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
